New Board member
Sven Andréasson has been appointed member of the Board of cancer vaccine company Immunicum AB (publ) in Gothenburg, Sweden. He succeeds Bengt Andersson, who will instead be included in the Company’s Scientific Advisory Board.
Sven Andréasson has many years of experience in both pharmaceutical and biotechnology companies. He was CEO of Active Biotech AB in Lund between 1999 and 2008 and then president of Beta – Cell NV in Brussels. Since March 2012 to November 2013, he was CEO of Isconova AB in Uppsala. After Novavax Inc’s. acquisition, he is Director of Novavax AB. He has held senior positions in the international pharmaceutical industry, including as President and Vice President in, essentially, Swedish, French, Belgian and German companies within the Pharmacia Group. Other directorships: XImmune AB, Lund (Chairman), Erytech SA, Lyon, Cell Astra Inc., San Francisco, Novavax AB, Uppsala and OIL AB, Stockholm, Sweden (Chairman).